Lymphocyte immunotherapy for recurrent spontaneous abortion in patients with negative blocking antibody

Randomized trials of lymphocytes immunotherapy (LIT) in the treatment for recurrent spontaneous abortion (RSA) have shown conflicting results. Current evidences to evaluate the effectiveness of LIT for RSA patients who lack of blocking antibody (BA) are systematic reviewed as a purpose. Literatures concern RSA patients with negative BA and who receiving LIT were searched and screened. Pregnancy rates for each treatment group were extracted, and the overall odds ratio (OR) and absolute treatment effect for LIT were calculated. According to the literatures, results of 14 randomized, double-blind trials comparing LIT with placebo for the treatment of RSA included in the meta-analysis were shown as follows: pregnancy rate is better in LIT (OR=5.72, 95% CI 4.42-7.40, P<0.00001) and the positive BA group (OR=1.58, 95% CI 1.36-1.82, P<0.00001) than in the NLIT negative BA group after LIT respectively. Moreover, low abortion rate was found in LIT group (OR=0.19, 95% CI 0.14-0.24, P<0.00001) and the positive BA group (OR=0.15, 95% CI 0.10-0.24, P<0.00001). Irrelevant to the source of lymphocytes, LIT displayed good therapeutic effect (OR=5.09, 95% CI 3.83-6.76, P<0.00001). This meta-analysis suggests that no matter lymphocytes from, LIT may be beneficial to the treatment of RSA patients with negative BA, improving the pregnancy rate and reducing the abortion rate.